APPLICATION NUMBER:
21-449

CORRESPONDENCE
June 7, 2002

Food and Drug Administration, CDER
Division of Antiviral Drug Products (HFD-530)
Attention: Ms. Marsha Holloman
9201 Corporate Blvd., 1st Floor Document Room
Rockville, MD 20850

Subject: NDA 21-449: NDA Safety Update (GSI Reference No. 010)

Dear Ms. Holloman:

Gilead Sciences (Gilead) hereby submits the NDA Safety Update for adefovir dipivoxil 10 mg for the treatment of chronic hepatitis B. The content of the Safety Update report is in accordance with the proposal submitted for the Agency’s review on January 17, 2002 (Serial No. 264) and subsequent discussions between Gilead and the Agency during a teleconference on January 22, 2002. The Safety Update also includes targeted efficacy analyses for patients who have had a liver transplantation and patients who are waitlisted for liver transplantation (study GS-98-435) in order to assist in the risk-benefit assessment of adefovir dipivoxil in this patient population. While the risk-benefit assessment is presented in the body of the Safety Update report, the targeted efficacy analyses are provided in Appendix 5 to assure that they will not disturb the review of the safety data.

In conjunction with the NDA Safety Update, Gilead is revising the proposed Package Insert (PI) in order to incorporate the additional and new safety information included in the Safety Update. We will submit the revised PI under separate cover.

Please contact me at 650-522-5722 or via facsimile at 650-522-5489 if you have any questions or need additional information. You may also contact Alan Taylor, Ph.D., Vice President of Regulatory Affairs, at 650-522-5754. We share the same facsimile number.

Sincerely,

-Martine Kraus
Martine Kraus, Ph.D.
Director, Regulatory Affairs

Enclosure: 1 original (Volumes 1 to 17), 1 review copy (Volumes 1 to 17), 3 reviewer desk copies (Volumes 1 to 3), 1 desk copy (Volumes 1 to 3) including CD with electronic file for Marsha Holloman